Skip to main content

Table 3 Multivariate analysis of the factors associated with the prescription of abiraterone acetate plus prednisone

From: Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Factors

Beta

p-value

OR (95% CI)

Intercept

−2.713

0.109

 

Age

0.057

0.015

1.06 (1.01 to 1.11)

LDH

−1.120

0.009

0.33 (0.14 to 0.76)

  1. CI, confidence interval: LDH, lactate dehydrogenase; OR, odds ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us